Galectin-3 concentrations in response to an exhaustive aerobic exercise
محورهای موضوعی : Journal of Physical Activity and HormonesMohammad Ghassami 1 , Saeid Naraghi 2
1 - MS in exercise physiology, Department of Exercise physiology, Marvdasht branch, Islamic Azad University, Marvdasht, Iran
2 - MS in exercise physiology, Department of Exercise physiology, Marvdasht branch, Islamic Azad University, Marvdasht, Iran
کلید واژه: Heart failure, biomarker, Galectin-3, Exhaustive aerobic exercise,
چکیده مقاله :
Introduction: Elevated levels of galectin-3 have been found to be significantly associated with higher risk of death in both acute decompensate heart failure and chronic heart failure populations. Although endurance exercise is a crucial element in cardiovascular disease prevention, the relationship between exercise and plasma levels of galectin-3 is still unknown. The aim of this study was to determine the effect of an exhaustive aerobic exercise on galectin-3 levels in healthy males. Material & Methods: Fifteen healthy male (aged: 22.2 ± 2.3 years; ± SD) volunteered to participate in this study. The subjects were performed Bruce protocol as the exhaustive aerobic exercise. The blood sample was taken before and immediately after the completion of the exhaustive aerobic exercise. Wilcoxon test and Spearman correlation test were used to analyze the data. Results: The results demonstrated that galectin-3 had no significant changes in response to the exhaustive aerobic exercise (297.6 ± 180.5 vs. 294.9 ± 190.3 pg/ml). No significant correlation was observed between the post-exercise levels of galectin-3 with body mass (r = 0.1, P = 0.7), BMI (r = ‒ 0.1, P = 0.7), body fat percentage (r = 0.06, P = 0.8), WHR (r = 0.02, P = 0.9), or VO2max (r = 0.2, P = 0.4). Conclusions: In conclusion, the exhaustive aerobic exercise had not significant effects on galectin-3 concentrations in healthy individuals.
1. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807-20810.
2. Rapoport EM, Kurmyshkina OV, Bovin NV. Mammalian galectins: structure, carbohydrate specificity, and functions. Biochemistry (Mosc) 2008; 73: 393-405.
3. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-635.
4. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31: 655-662.
5. Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010; 1183: 158-182.
6. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
7. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013; 6: 219-226.
8. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study. Am Heart J 2014; 167: 674-682.
9. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-2081.
10. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 2011; 17: 7035-7046.
11. Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM, Yu LG. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res 2013; 19: 1693-1704.
12. Kwan G and Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation 2012; 125: e369-e373.
13. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 2012; 19: 403-488.
14. Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y, et al. Atrial Fibrillation Promotion by Endurance Exercise: Demonstration and Mechanistic Exploration in an Animal Model. J Am Coll Cardiol 2013; 62: 68-77.
15. Gay-Jordi G, Guash E, Benito B, Brugada J, Nattel S, Mont L, et al. Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. PLoS One 2013; 8: e55427.
16. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. Exercise induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J 2011; 33: 998-1006.
17. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace 2009; 11: 1156-1159.
18. Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross country skiers: echocardiographic findings and possible predictors – a 28–30 years follow-up study. Eur J Cardiovasc Prev Rehabil 2010; 17: 100-105.
19. Jensen-Urstad K, Bouvier F, Saltin B, Jensen-Urstad M. High prevalence of arrhythmias in elderly male athletes with a lifelong history of regular strenuous exercise. Heart 1998; 79: 161-164.
20. Ilbeigi S, Saeedi H, Afzalpour ME, Haghighi A, Heidarian M, Haghighi M, et al. The effect of an exhausting aerobic exercise session on plasma NT-proBNP and galectine-3 levels in male runners. J Physic Act Horm 2017; 1: 65-74.
21. Khajeian N, Moghadasi M. Effect of 8 weeks regular endurance training on galectin-3 changes after a strenuous aerobic exercise. J Physic Act Horm 2017; 1: 29-38.
22. Rabinovich GA, Toscano M A. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338-352.
23. Clementy N, Benhenda N, Piver E, Pierre B, Bernard A, Fauchier L, et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep 2016; 6: 34357.
24. Libhaber E, Woodiwiss AJ, Raymond A, Gomes M, Maseko MJ, Sareli P, et al. Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample. Hypertension 2015; 65: 1356-1364.
25. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 2014; 167: 853-860.
26. Wu CK, Su MY, Lee JK, Chiang FT, Hwang JJ, Lin JL, et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep 2015; 5:17007.
27. Takemoto Y, Ramirez RJ, Yokokawa M, Kaur K, Ponce-Balbuena D, Sinno MC, et al. Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes. JACC Basic Transl Sci 2016; 1: 143-154.
28. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68.
29. Salvagno GL, Schena F, Gelati M, Danese E, Cervellin G, Guidi GC, et al. The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon. Clin Chem Lab Med 2014; 52: 267-272.
30. Lippi G, Banfi G, Botrè F, de la Torre X, De Vita F, Gomez-Cabrera MC, et al. Laboratory medicine and sports: between Scylla and Charybdis. Clin Chem Lab Med 2012; 50: 1309-16.
31. Hättasch R, Spethmann S, de Boer RA, Ruifrok WP, Schattke S, Wagner M, et al. Galectin-3 increase in endurance athletes. Europ J prevent cardiol 2013; 21: 1192-1199.
32. Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Jover E, García-Alberola A, et al. Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. Sci Rep 2017; 7: 40378.
33. Kornej J, Schmidl J, Ueberham L, John S, Daneschnejad S, Dinov B, et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One 2015; 10: e0123574.
34. López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 2015; 17: 385-392.
35. Besler C, Lang D, Urban D, Rommel KP, von Roeder M, Fengler K, et al. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Circ Heart Fail 2017; 10: e003804.
36. Zamora E, Lupón J, de Antonio M, Galán A, Domingo M, Urrutia A, et al. Renal function largely influences Galectin-3 prognostic value in heart failure. Int J Cardiol 2014; 177: 171-177.
37. Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J Am Soc Nephrol 2015; 26: 2213-2221.
38. Dick SA, Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res 2016; 119: 159-176.
39. Peacock WF. How galectin-3 changes acute heart failure decision making in the emergency department. Clin Chem Lab Med 2014; 52: 1409-1412.
40. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23: 570-578.
41. Nguyen MN, Su Y, Vizi D, Fang L, Elims AH, Zhao WB, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Scientific Rep 2018; 8: 8213-8225.
